Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM24I0N)

Drug Name
PF-4878691 Drug Info
Synonyms PF-04878691; PF-4171455
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [1]
Hepatitis C virus infection 1E51.1 Phase 1 [2]
Cross-matching ID
PubChem CID
10309114
CAS Number
CAS 532959-63-0
TTD Drug ID
DM24I0N

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Agonist [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Toll-like receptor 7 (TLR7) DTT TLR7 3.7 0.848 -0.152 3.121
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 7 (TLR7) DTT TLR7 3.32E-25 0.44 0.88
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00189332) Use of 852A in Metastatic Cutaneous Melanoma.. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00810758) Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691. U.S. National Institutes of Health.
3 The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9.